The protocol presented here details a technique which enables the neurotrophins nerve growth factor (NGF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) to be labelled using 125I and the bioactivity of these labelled proteins determined using an in vivo bioassay. We have found that the simplest and most effective method for 125I-labelling of neurotrophic factors is the IODO-GEN method. Following the iodination of neurotrophins it must be established that the labelling procedure has not affected the biological activity of the protein. Traditional methods of assaying the bioactivity of 125I-labelled neurotrophins have several disadvantages and a much easier protocol to use is the retrograde axonal transport of these proteins in sympathetic and sensory neurons of adult mice. High specific activity 125I-labelled neurotrophin, to which known amounts of unlabelled neurotrophin are added, is injected into the right anterior eye chamber of adult mice under anaesthetic and the animals are left to recover for 16 h, after which they are sacrificed and both superior cervical ganglia (SCG) and trigeminal ganglia (TGG) are removed. The accumulated radioactivity in each ganglion is determined using a gamma-counter and the amount of neurotrophin transported is calculated by subtracting the counts obtained on the non-injected side from those present on the injected side. By comparing the amount of protein injected with the amount transported, the specific activity of the bioactive labelled neurotrophin can be determined.